



Secretory immunity in Balb/c mice against *Salmonella typhimurium*
by Steven Richard Shope

A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science in
Microbiology

Montana State University

© Copyright by Steven Richard Shope (1990)

Abstract:

Experiments were designed to test the ability of avirulent mutants of *Salmonella typhimurium* to induce secretory immune responses in mice and demonstrate the passive transfer of protection resulting from these immune responses to foster pups. *S. typhimurium* Aro- mutant SL3235 and *cya crp* mutant X4064 retained the ability to adhere to and invade intestinal epithelial cells in tissue culture assays. Findings demonstrated that plasmid loss did not alter the ability of *S. typhimurium* to adhere to and invade epithelial cells in vitro. Subcutaneous priming using live avirulent *S. typhimurium* with adjuvant followed by oral exposure to the same organism was used to immunize two groups of mice. One group of mice was immunized using 3 oral exposures through drinking-water to live avirulent *S. typhimurium*. Using an immunoassay to measure specific antibody in the feces of immunized mice, it was determined that subcutaneous priming was not an effective method for inducing reproducible intestinal immune responses. In contrast, mice immunized using multiple oral exposures demonstrated strong intestinal responses characterized by specific IgA production and a memory response. The production of protective antibody resulting from the induction of a secretory response was demonstrated by the passive transfer of protection to foster pups. The survival time for 50% of foster pups placed with immunized mothers was at least two times greater than controls consisting of foster pups placed with unimmunized mothers.

SECRETORY IMMUNITY IN BALB/C MICE
AGAINST *SALMONELLA TYPHIMURIUM*

by

Steven Richard Shope

A thesis submitted in partial fulfillment
of the requirements for the degree

of

Master of Science

in

Microbiology

MONTANA STATE UNIVERSITY
Bozeman, Montana

July 1990

N378
Sh 725

APPROVAL

of a thesis submitted by

Steven Richard Shope

This thesis has been read by each member of the thesis committee and has been found to be satisfactory regarding content, English usage, format, citations, bibliographic style, and consistency, and is ready for submission to the College of Graduate Studies.

8-14-90
Date

D. A. Schumann
Chairperson, Graduate Committee

Approved for Major Department

8-31-90
Date

[Signature]
Head, Major Department

Approved for the College of Graduate Studies

8/31/90
Date


[Signature]
Graduate Dean

STATEMENT OF PERMISSION TO USE

In presenting this thesis in partial fulfillment of the requirements for a master's degree at Montana State University, I agree that the Library shall make it available to borrowers under the rules of the Library. Brief quotations from this thesis are allowable without special permission, provided that accurate acknowledgment of source is made.

Permission for extensive quotation from or reproduction of this thesis may be granted by my major professor, or in his absence, by the Dean of Libraries when, in the opinion of either, the proposed use of the material is for scholarly purposes. Any copying or use of the material in this thesis for financial gain shall not be allowed without my written permission.

Signature



Date

7/24/90

TABLE OF CONTENTS

	Page
LIST OF TABLES.....	vii
LIST OF FIGURES.....	viii
ABSTRACT.....	xi
INTRODUCTION.....	1
<i>Salmonella typhimurium</i>	1
The Pathogenesis of <i>S. typhimurium</i>	2
The Invasion of Host Epithelial Cells.....	3
Survival in the Host.....	5
Plasmid Associated Virulence.....	5
Other Virulence Properties of <i>S. typhimurium</i>	6
Host Defenses Against Colonization by <i>S. typhimurium</i>	6
Mucosal Immunity.....	7
The Uptake of Antigen from the Gut.....	8
B-cell Differentiation and Migration.....	8
Secretory IgA (SIgA).....	9
Stimulation of Mucosal Immunity.....	12
Statement of Research Problem.....	14
MATERIALS AND METHODS.....	15
Bacterial Strains.....	15
Storage of Cultures.....	17
Preparation and Handling of Bacteria.....	18
Development of Standard Curves for Bacterial Strains.....	19
Tissue Culture Attachment and Invasion Assay.....	19
Preparation and Maintenance of Monolayers.....	20
Preparation of Bacteria for Tissue Culture Assays.....	21
Tissue Culture Attachment and Invasion Assay...	22
Preparation of Infected Cells for Electron Microscopy.....	24
Plasmid Preparation and Analysis.....	25
Preparation of Plasmids from Bacterial Strains..	25
Analysis of Plasmids Using Gel Electrophoresis..	26
Sizing Plasmids.....	26

TABLE OF CONTENTS (Continued)

	Page
Animal Experimentation and Immunological Assays.....	27
Immunization of Balb/cBy Mice.....	27
Subcutaneous Immunization.....	27
Manual Oral Immunization.....	28
Drinking-water Immunization.....	28
Feces Collection.....	29
Serum Collection.....	30
ELISA.....	30
Preparation of the Antigen.....	30
Preparation of ELISA Plates.....	31
The ELISA Procedure.....	32
Foster Pup Studies.....	33
Feeding Studies.....	34
Abbreviations.....	35
 RESULTS.....	 37
Plasmid Analysis.....	37
Attachment and Invasion Assay.....	40
Microscopic Evaluation of Attachment and Invasion..	45
Foster Pup Studies.....	49
Inducing Specific Secretory Immune Responses in Immunized Mice.....	49
SL3235 Experimental Group #1.....	50
X4064 Experimental Group #1.....	50
SL3235 Experimental Group #2.....	51
Passive Transfer of Protection to Foster Pups..	52
SL3235 Experimental Group #1.....	60
X4064 Experimental Group #1.....	61
SL3235 Experimental Group #2.....	62
Passive Feeding Studies.....	63
 DISCUSSION.....	 64
Characterization of Experimental Strains.....	65
Plasmid Analysis.....	65
<i>In vitro</i> Adhesion and Invasion.....	66
Microscopic Evaluation of Attachment and Invasion.....	69
Responses to Oral Immunization.....	70
Passive Transfer of Protection to Foster Infant Mice.....	73
Feeding Studies.....	76
Conclusions.....	76
 LITERATURE CITED.....	 78

TABLE OF CONTENTS (Continued)

	Page
APPENDICES.....	87
Appendix A-Preparation of Samples for Microscopy...	88
Appendix B-Preparation of Plasmids.....	90
Appendix C-Preparation of Hybridomas.....	93
Immunization Protocols.....	94
Preparation of Spleen Cells.....	94
Preparation of Myeloma Cells.....	95
Fusion Protocol.....	95
Antibody Screening Assay.....	96
Cloning and Expansion.....	97
Ascites Production.....	98
Appendix D-Ammonium Sulfate Precipitation of Immunoglobulins from Feces Samples.....	99
Appendix E-Standard Curve for Plasmid Sizing.....	101
Appendix F-Supplemental Graphs for Experimental Group SL3235 #1.....	103
Appendix G-Supplemental Graphs for Experimental Group X4064 #1.....	108
Appendix H-Standard Curve for Strain SL3201.....	113

LIST OF TABLES

Table	Page
1. Plasmids of the <i>S. typhimurium</i> strains used in this study.....	37
2. A comparison between the <i>in vitro</i> interactions of <i>S. typhimurium</i> strain SL3201 grown under aerobic and anaerobic conditions with Henle 407 intestinal epithelial cells.....	42
3. A comparison between the <i>in vitro</i> interactions of <i>S. typhimurium</i> grown at 25°C and 35°C with Henle 407 intestinal epithelial cells.....	42
4. Interaction of the avirulent <i>S. typhimurium</i> mutant SL3235 grown under anaerobic conditions with Henle 407 intestinal epithelial cells.....	43
5. Interaction of the avirulent <i>S. typhimurium</i> mutant X4064 grown under anaerobic conditions with Henle 407 intestinal epithelial cells.....	44
6. Interaction of the plasmid-cured strain <i>S. typhimurium</i> strain X3337 grown under anaerobic conditions with Henle 407 intestinal epithelial cells.....	44
7. Titers of specific IgA, IgM, and IgG present in the serum of immunized and unimmunized control mice prior to and following multiple drinking-water immunizations with <i>S. typhimurium</i> strain SL3235.....	52
8. Feeding study results demonstrating the frequency of isolation of Group A <i>S. typhimurium</i> from the spleens and rectums of challenged mice.....	63

LIST OF FIGURES

Figure	Page
1. Agarose gel electrophoresis of plasmids obtained from <i>S. typhimurium</i> strains.....	38
2. Agarose gel electrophoresis of plasmid standards and plasmids obtained from <i>S. typhimurium</i> strains.	39
3. Transmission electron micrograph of Henle cells infected with <i>S. typhimurium</i>	46
4. Transmission electron micrograph of Henle cells infected with <i>S. typhimurium</i>	47
5. Transmission electron micrograph of Henle cells infected with <i>S. typhimurium</i>	48
6. Relative amounts of IgA, IgM, and IgG in the feces of immunized control mouse S1 prior to and following drinking-water immunization with <i>S. typhimurium</i> strain SL3235.....	53
7. Relative amounts of IgA, IgM, and IgG in the feces of immunized control mouse S6 prior to and following drinking-water immunization with <i>S. typhimurium</i> strain X4064.....	54
8. Relative amounts of specific IgA, IgM, and IgG present in the feces of immunized control mouse 13 prior to, during, and following the administration of multiple drinking-water immunizations with <i>S. typhimurium</i> strain SL3235.....	55
9. Relative amounts of specific IgA, IgM, and IgG present in the feces of immunized control mouse 14 prior to, during, and following the administration of multiple drinking-water immunizations with <i>S. typhimurium</i> strain SL3235.....	56
10. Relative amounts of specific IgA, IgM, and IgG present in the feces of immunized control mouse 15 prior to, during, and following the administration of multiple drinking-water immunizations with <i>S. typhimurium</i> strain SL3235.....	57

LIST OF FIGURES (Continued)

Figure	Page
11. Relative amounts of specific IgA, IgM, and IgG present in the feces of immunized control mouse 16 prior to, during, and following the administration of multiple drinking-water immunizations with <i>S. typhimurium</i> strain SL3235.....	58
12. Relative amounts of specific IgA, IgM, and IgG present in the feces of immunized control mouse 17 prior to, during, and following the administration of multiple drinking-water immunizations with <i>S. typhimurium</i> strain SL3235.....	59
13. Results of the first SL3235 foster pup experiment demonstrating the survival time of individual passively immunized and non-immunized mice which were challenged with virulent <i>S. typhimurium</i> strain SL3201.....	60
14. Results of the X4064 foster pup experiment comparing the percent survival of passively-immunized mice (n=15) with the percent survival in a group of unimmunized control mice (n=16) following challenge with virulent <i>S. typhimurium</i> strain SL3201 over time.....	61
15. Results of the SL3235 foster pup experiment comparing the percent survival of passively-immunized mice (n=24) with the percent survival in a group of unimmunized control mice (n=24) following challenge with virulent <i>S. typhimurium</i> strain SL3201 over time.....	62
16. Distance migrated by plasmid standards relative to their size.....	102
17. Relative amounts of IgA, IgM, and IgG in the feces of immunized control mouse S2 prior to and following drinking-water immunization with <i>S. typhimurium</i> strain SL3235.....	104
18. Relative amounts of IgA, IgM, and IgG in the feces of immunized control mouse S3 prior to and following drinking-water immunization with <i>S. typhimurium</i> strain SL3235.....	105
19. Relative amounts of IgA, IgM, and IgG in the feces of immunized control mouse S4 prior to and following drinking-water immunization with <i>S. typhimurium</i> strain SL3235.....	106

LIST OF FIGURES (Continued)

Figure		Page
20.	Relative amounts of IgA, IgM, and IgG in the feces of immunized control mouse S5 prior to and following drinking-water immunization with <i>S. typhimurium</i> strain SL3235.....	107
21.	Relative amounts of IgA, IgM, and IgG in the feces of immunized control mouse S7 prior to and following drinking-water immunization with <i>S. typhimurium</i> strain X4064.....	109
22.	Relative amounts of IgA, IgM, and IgG in the feces of immunized control mouse S8 prior to and following drinking-water immunization with <i>S. typhimurium</i> strain X4064.....	110
23.	Relative amounts of IgA, IgM, and IgG in the feces of immunized control mouse S9 prior to and following drinking-water immunization with <i>S. typhimurium</i> strain X4064.....	111
24.	Relative amounts of IgA, IgM, and IgG in the feces of immunized control mouse S10 prior to and following drinking-water immunization with <i>S. typhimurium</i> strain X4064.....	112

ABSTRACT

Experiments were designed to test the ability of avirulent mutants of *Salmonella typhimurium* to induce secretory immune responses in mice and demonstrate the passive transfer of protection resulting from these immune responses to foster pups. *S. typhimurium* Aro- mutant SL3235 and *cya crp* mutant X4064 retained the ability to adhere to and invade intestinal epithelial cells in tissue culture assays. Findings demonstrated that plasmid loss did not alter the ability of *S. typhimurium* to adhere to and invade epithelial cells *in vitro*. Subcutaneous priming using live avirulent *S. typhimurium* with adjuvant followed by oral exposure to the same organism was used to immunize two groups of mice. One group of mice was immunized using 3 oral exposures through drinking-water to live avirulent *S. typhimurium*. Using an immunoassay to measure specific antibody in the feces of immunized mice, it was determined that subcutaneous priming was not an effective method for inducing reproducible intestinal immune responses. In contrast, mice immunized using multiple oral exposures demonstrated strong intestinal responses characterized by specific IgA production and a memory response. The production of protective antibody resulting from the induction of a secretory response was demonstrated by the passive transfer of protection to foster pups. The survival time for 50% of foster pups placed with immunized mothers was at least two times greater than controls consisting of foster pups placed with unimmunized mothers.

INTRODUCTION

Salmonella typhimurium

S. typhimurium is a member of a group of bacteria consisting of more than 2,000 serotypes as described by the serotyping scheme of Kauffmann and White (21). This organism as a member of the genus *Salmonella* in the family Enterobacteriaceae is a gram-negative, facultative anaerobic, peritrichously flagellated rod which produces gas from glucose. It is a facultative intracellular enteric pathogen which does not ferment lactose.

Salmonellosis, a human enteric disease caused by representatives of the *Salmonella* serotype group, is considered an important medical problem in the United States (13). The number of cases reported annually to the CDC is approximately 40,000 (13), but these cases probably represent only a small fraction of the number of cases which occur in the United States (13,63). Estimates have indicated that as many as 800,000 to 5,300,000 cases may occur annually in this country (13,63), with as many 9,000 deaths resulting from these cases. CDC reports from 1983 cite *S. typhimurium*, *S. enteritidis*, *S. heidelberg*, and *S. newport* as the four most common serotypes isolated from human sources, *S. typhimurium* being the most common of these four with 13,172

isolates (12). Most human cases of salmonellosis come from foodborne sources (58). Poultry, meat, and dairy products are the most important vehicles in the transmission of the disease (13). *S. typhimurium* infections in certain inbred strains of mice mimic a more serious human disease. Murine salmonellosis in mice homozygous for the chromosome 1 allele *Ity^s* caused by this organism is commonly regarded as an analogous disease to human typhoid fever and offers a good model for the study of this disease (38).

Hoiseith *et al.* (37) and Dougan *et al.* (18) described the construction and preliminary testing of several avirulent auxotrophic mutants of *S. typhimurium*. Curtiss *et al.* (16) constructed a mutant lacking adenylate cyclase and the cyclic AMP receptor protein which exhibited reduced virulence in mice. These mutants as well as others, such as the mutants deficient in the enzyme UDP-glucose-4-epimerase (*galE* mutants) (14) have been the subject of testing with regard to their ability to effectively elicit an immune response protective against challenge from their virulent counter-parts (14,16,18,32,37,46,47,56,59,65).

The Pathogenesis of *S. typhimurium*

The pathogenesis of *S. typhimurium* infections in a murine host can be divided into two steps: (i) The invasion of epithelial cells of the gastrointestinal mucosa and migration

of the organism through the epithelial cell layer to the underlying lymphoid tissue. (ii) The survival, replication and migration of the organism within the hosts lymphoid and reticuloendothelial system (RES).

The Invasion of Host Epithelial Cells

Once *Salmonella* have been ingested, the first interaction with the host is attachment to the gastrointestinal mucosa. In its simplest form, this attachment requires the participation of two factors: (i) receptors present on the surface of the eukaryotic cells; and (ii) adhesin located on the surface of the bacterial cell (24). The bacterial adhesin(s) of *S. typhimurium* have yet to be clearly defined. Fimbriae and a mannose-resistant hemagglutinin have been proposed as possible adhesins, but non-fimbriated strains of *S. typhimurium* are as virulent as fimbriated strains when fed orally to mice (24,40). During the process of attachment, the invading organism proceeds through two phases: an unstable reversible form of attachment involving hydrophobic interactions, and a more stable, irreversible form of attachment involving adhesin-receptor interactions (41). It was proposed by Finlay et al. (25,27) that during the initial interactions between cell and bacteria several proteins are induced on the surface of the invading organism by eukaryotic proteins leading to the more stable irreversible form of attachment and eventual internalization.

Internalization of the organism into host cells is a process that requires the synthesis of several bacterial proteins. It has been proposed that these proteins are also induced by cell-bacteria interactions but that they are not the same proteins which mediate stable attachment (29). Galan *et al.* (29) isolated and described a genetic locus, *inv*, which was necessary for wild-type *S. typhimurium* strains to penetrate epithelial cells *in vitro*. This group of workers also found that while the proteins encoded by this locus were necessary for the internalization of the organism they were not necessary for the initiation of stable attachment. The invading organism is enclosed in a membrane bound vacuole as it enters the cell through a process similar to phagocytosis that actively involves cellular microfilaments but not acidification of the vacuole which is an important part of endocytic pathways (23). Each invading organism enters the cell in a separate vacuole which later coalesce into one large intracellular vacuole (24). *Salmonella* replicate within these vacuoles and appear to remain vacuolized following this replication (23). Finlay *et al.* (25,26) used polarized Madin Darby canine kidney epithelial cell cultures to demonstrate the transcytosis of *Salmonella*. It was shown that *Salmonella* do not use any pre-existing pathway for intracellular transport through the epithelial cell. Instead, most of the invading organisms remain within the cell, with only a few exiting to either the apical or basolateral epithelial cell

surface. *In vivo*, the successful penetration of a few microorganisms through the epithelium is probably sufficient to cause disease (25,26).

Survival in the Host

Once through the intestinal barrier, the invading organism passes through the lamina propria and into the gut associated lymphoid tissue (GALT). *S. typhimurium* colonizes the Peyer's patches, invades into draining mesenteric lymph nodes, and, due to *S. typhimurium's* resistance to killing by phagocytic cells, spreads through the lymphatic system to the liver and spleen (30). *S. typhimurium's* resistance to the bactericidal activity of serum complement allows a disseminated systemic infection to follow.

Plasmid Associated Virulence. It appears that a 60 megadalton (Mdal) "cryptic" plasmid [100 kilobases (kb)] is responsible for *S. typhimurium's* antiphagocytic properties (33,36) and resistance to the activity of serum complement as determined by the structure of the organisms lipopolysaccharide (LPS) (33,34,70), although there has been some argument concerning whether or not resistance to phagocytosis and the activity of serum complement can be attributed to this organism (30,31). Colonization of Peyer's patches was found not to be mediated by the cryptic plasmid (30,33) as proposed by Jones et al. (39), but the plasmid was found to be involved in the infection of the spleen and

mesenteric lymph nodes following peroral (po) inoculation of mice (30).

Other Virulence Associated Properties of *S. typhimurium*.

The survival and replication of *S. typhimurium* in the cells of the RES (polymorphs and macrophages) are attributes which have been associated with the virulence of this organism. While there is some evidence demonstrating the possibility of a mechanism involving the survival of *S. typhimurium* within murine macrophages (11,71), data supporting replication of *S. typhimurium* within murine macrophages is limited (38). Hsu (38) has indicated that observations of the replication of *S. typhimurium* within murine macrophages is based on the artifacts in crude experimental procedures and the erroneous assumption that because the liver and spleen are organs of the RES, organisms are trapped by and replicate within resident macrophages (Kupffer cells). It has been proposed by Hsu that *S. typhimurium* proliferates in the sinusoids and intercellular spaces found in the liver and spleen, not in the resident macrophages.

Host Defenses Against Colonization
by *Salmonella typhimurium*

The gastrointestinal mucosa is the first barrier which an enteroinvasive bacteria such as *S. typhimurium* must adhere to and cross in order to effectively colonize its host. This barrier is defended by the cooperative action of specific

immunoglobulins derived from the mucosal immune system and innate nonspecific factors such as the mucous layer coating the mucosa (55). Together, the specific action of secretory IgA (SIgA) and IgM binding an antigen, the nonspecific interactions which trap SIgA coated antigens in the mucus layer of the intestine, and the shedding of the trapped antigen from the gastrointestinal tract form a protective process termed immune or antigen exclusion (8,50,52).

Mucosal Immunity

The existence of a protective local immune system that seemed to function independently of systemic immunity was initially proposed by Besredka early in this century (7). It was not until 1965 that the molecular basis for local immunity was established when Tomasi *et al.* confirmed the external secretions contained a unique immunoglobulin subsequently called SIgA (7). It is now known that a functional local immune system which is mediated by secretory tissue and is independent of the humoral immune system exists (7,8,69).

The exocrine secretory tissues constitute the most important mediator of specific immunity with the intestinal mucosa being the greatest contributor (7). Estimates indicate that roughly 70-80% of all immunoglobulin producing cells in the human are located in the gastrointestinal mucosa (7).

The Uptake of Antigen from the Gut. The defense system of the gastrointestinal mucosa is based on the continuous surveillance of luminal antigens by specialized antigen transport mechanisms in the Peyer's patches and the epithelium (55). Antigen present in the gut lumen is taken up and transported into the Peyer's patches either by specialized microfold (M) cells located in the intestinal epithelium in close association with intraepithelial lymphocytes or by MHC class II-positive epithelial cells (7,55). The antigen is then either processed by a macrophage and presented to a T cell by a MHC class II-positive dendritic cell, presented directly to a T cell by a MHC class II-positive dendritic cell, or presented directly to a T cell by a MHC class II-positive epithelial cell (7).

B-cell Differentiation and Migration. T-cells activated by the presentation of the antigen provide various regulatory "first signals" (gamma-interferon and possibly interleukins 2, 5, and 6) to the B-cell which induce B-cell differentiation (IgM or IgA expression) (7,8,53,67). Early studies showed that clonal immaturity, as evidenced by the potential for J-chain production, combined with prominent IgA expression characterize the B-cells that migrate to secretory tissue from the Peyer's patches (7). But more recent studies indicate that the majority of Peyer's patch derived cells arriving in the intestinal mucosa are not IgA expressing cells but belong

to a population of IgM and IgD bearing memory cells (8). Such lymphocytes were probably exposed to stimulatory "first signals" and require "second signals" in order to further differentiate and divide into IgA-producing immunocytes (8,67). These "second signals" are most likely encountered as the B-cell migrates through the mesenteric lymph nodes and spleen and in the gut mucosa or secretory tissue where they end up (8,67).

Several hypotheses have been put forward to explain the migration of B-cells to secretory tissue after their initial differentiation: (i) The stimulated B-cells have an affinity for secretory component (SC) which directs them to the glandular epithelium where SC is expressed. (ii) Epithelial class II MHC molecules act to direct the B-cells to secretory epithelial tissue. (iii) Unidentified epithelial factor(s) expressed in secretory tissue may selectively attract certain lymphoid cell populations such as the stimulated B-cells (7,8).

Secretory IgA (SIgA). SIgA is the major species of immunoglobulin synthesized and secreted as the result of the induction of a mucosal immune response, with IgM playing a minor role (7,8,55,67). Complete SIgA is characterized by two immunoglobulin molecules (molecular weight of approximately 190,000) (alpha heavy chains) cross-linked by a J-chain (molecular weight of approximately 15,000) and complexed with

one SC molecule (molecular weight of approximately 80,000) (8). The IgA dimer becomes complexed with an SC molecule as it interacts with a glandular epithelial cell. It has been proposed by Brandtzaeg (6,7) that the SC molecule acts as a glandular cell membrane receptor for J-chain containing immunoglobulins, and that the receptor-substrate complexes formed on the cell surface are taken up by absorptive pinocytosis for secretion into the intestinal lumen. SIgA has a broad specificity which allows it to recognize antigens which are slightly altered due to antigenic drift (69). The structure of the complete SIgA molecule also confers an inherent resistance to enzymatic digestion and low pH to the molecule which is necessary for the survival and activity of SIgA in the gut lumen (2,8,55).

SIgA's mode of action differs from that of IgG and IgM in that it does not exert its effectiveness through complement activation or opsonization, rather as an efficient cross-linking agent and possibly by mediating the inhibition of the ability of organisms to adhere to the mucosa (50,72). It has been shown that antigen bound by SIgA is not absorbed by the gut but remains in the lumen (1). Magnusson *et al.* (50) described two protective properties which SIgA offers to the gastrointestinal mucosa: (i) The binding of antigens by SIgA increases their affinity for the mucus lining of the intestine promoting immune exclusion at the mucosal membranes.

(ii) SIgA modifies IgG-mediated phagocytosis as well as the general surface properties of bacteria, thereby possibly depressing local inflammatory responses at the mucosa. Many studies have shown that bacteria bound to SIgA are prevented from associating with mucosal membranes by mechanisms of immune exclusion or by inhibition of adherence. The adherence of *Campylobacter jejuni* to epithelial cells *in vitro* was inhibited by SIgA-containing mucus (54). *In vitro* studies have also demonstrated that colostrum SIgA had the ability to decrease the association of *Salmonella* with tissue culture cells (49), and that the penetration of HeLa cells by invasive *Escherichia coli* could be inhibited by the presence of colostrum containing IgM (57). It has also been demonstrated *in vivo* that the presence of passively-provided immunoglobulins could inhibit the colonization of rabbits and humans by enteroinvasive or adherent organisms (4,9,10,19,57,68). Cantey (9) demonstrated that SIgA given passively could prevent the colonization of rabbits by non-piliated *E. coli* and that in the absence of IgA diarrhea would occur (10). Low-birth-weight infants fed human serum preparations containing 73% IgA were protected against enterocolitis (19). Tacket et al. (68) demonstrated that lyophilized immunoglobulins prepared from the colostrum of immunized cows could protect against challenge with enterotoxigenic *E. coli* when fed to human volunteers. Oral immunization with live avirulent bacteria has been shown to

induce an immune response protective against oral challenge by virulent organisms (22,28). Fierer et al. (22) demonstrated that a plasmid-cured strain of *Salmonella dublin* given orally to mice provided protection against a subsequent challenge with group B and D virulent *Salmonella* which left the intestinal walls, Peyer's patches, and mesenteric lymph nodes free of the challenge organism. Oral immunization with an *E. coli* strain carrying the invasion-mediating plasmid of *Shigella* provided protection to monkeys challenged by *Shigella* (28).

SIgA has also been shown to enhance the bacteriostatic effects of lactoferrin by inhibiting bacterial production of iron-chelating agents which may interfere with its activity, and it may also enhance the effect of the peroxidase defense system by some unknown mechanism (8).

Stimulation of Mucosal Immunity. Mucosal immunity can be stimulated by a variety of antigens as long as they possess one of two general characteristics: (i) special binding characteristics; or (ii) the ability to promote delivery into the GALT (17). Keren et al. (44,45) demonstrated the induction of a strong specific mucosal IgA memory response in parenterally primed rabbits orally immunized with live *Shigella*, where rabbits immunized with killed *Shigella* did not show such a response. Curtiss et al. (15) described the induction of a mucosal response in mice immunized orally with

an avirulent strain of *S. typhimurium* carrying the *SpaA* gene of *Streptococcus mutans* specificity to both the organism and the *SpaA* protein. Curtiss also indicated that oral immunization of mice with live avirulent aromatic mutants of *S. typhimurium* offered protection against challenge by a virulent strain of the same organism. Cholera toxin has been shown to stimulate a strong mucosal IgA memory response due to its ability to effectively enter the GALT (48).

The effectiveness of different immunization protocols in eliciting a strong mucosal memory response is still under investigation. The standard protocol for inducing a mucosal memory response has been to administer multiple oral doses of the antigen over a period of several weeks (43-45,48), but Keren *et al.* have demonstrated an effective method involving the use of a parenteral priming dose of the antigen (intravenous or subcutaneous) prior to the administration of an oral dose (43,44).

Statement of Research Problem

This study was undertaken to investigate the ability of mutant strains of *S. typhimurium* to elicit a specific protective secretory immune response. This study had three objectives: (i) to characterize these mutants with respect to their ability to adhere to and invade intestinal epithelial cells *in vitro*, and their plasmid profile relative to the virulent *S. typhimurium* strain SL3201; (ii) to induce a measurable and specific secretory immune response in Balb/cBy mice using these mutant strains; and (iii) to demonstrate protection provided by this response through the use of passive protection experiments with mouse foster pups.

MATERIALS AND METHODS

Bacterial Strains

The two strains of *S. typhimurium* of primary interest in this study were SL3235 and X4064. Both of these strains contain insertion mutations which are reflected in their inability to effectively colonize host tissue (16,37). This characteristic has generated interest in their use as live vaccines against virulent *S. typhimurium* (16,37,65)

Strain SL3235 was provided by B.A.D. Stocker, Stanford University School of Medicine. The mutation was constructed by the introduction of the transposon *aroA554::Tn10* into gene *aroA* of the virulent *S. typhimurium* strain SL3201 (37). This strain is a stable auxotrophic transductant (*aroA*-) which exhibits a requirement for both p-aminobenzoic acid (PABA) and 2,3-dihydroxybenzoic acid (DHB). The lack of these two metabolites in vertebrate tissues renders SL3235 unable to grow *in vivo*, and, therefore, is avirulent ($LD_{50} > 3 \times 10^6$ ip in Balb/cBy mice).

S. typhimurium strain X4064 was received from Roy Curtiss III, Washington University, St. Louis, Missouri. Strain X4064 contains stable insertion mutations ($\Delta cya, \Delta crp$) which block the synthesis of adenylate cyclase and cAMP receptor protein (CRP) (16). The mutant was constructed by the introduction

of transposon *cya::Tn10* and *crp::Tn10* into genes *cya* and *crp* of the virulent *S. typhimurium* SR-11 strain X3306, respectively. Without adenylate cyclase this organism cannot synthesize cyclic AMP (cAMP) which, along with CRP, is necessary for the transcription of many genes and operons associated with catabolic pathways (16). Cyclic AMP exerts positive control on systems used for the transport of fuel and carbon sources and on several amino acid permeases (16). Lysogeny of temperate phages, the synthesis pili, fimbriae, and flagella are also influenced by the concentration of cAMP within the organism (16). Exogenous sources of cAMP can be utilized by this strain, however, its activity is greatly reduced by the absence of CRP. X4064 exhibits a reduced ability to grow and a reduction in virulence ($LD_{50} > 1 \times 10^6$, ip in Balb/cBy mice) relative to its wild-type parent strain (16).

Other strains of *S. typhimurium* that were used in this study are SL3201, SL1306, and X3337. Strain SL3201 (obtained from B.A.D. Stocker) is a highly virulent ($LD_{50} < 20$ cells, ip in C57BL and Balb/cBy mice) example of the FIRN biotype (unable to produce fimbriae or to ferment inositol and rhamnose) (37). Strain 1306 (obtained from B.A.D. Stocker) carries a mutation in gene *galE* and is unable to synthesize UDP-galactose-4-epimerase, an enzyme important in the formation of LPS. Without this enzyme, strain SL1306 must synthesize LPS by an alternate pathway which leads to the

accumulation of the toxic precursors galactose-1-phosphate and UDP-galactose within the organism. Accompanying the build-up of these compounds is a reduction in the organisms ability to grow and its virulence (14,56). Strain X3337 (obtained from Roy Curtiss III) was previously cured of the 60 Mdal (100 Kb) plasmid which has been associated with the survival of *S. typhimurium* within animal hosts (30).

Several strains of *S. typhimurium* and *Escherichia coli* containing plasmids of known size were used to produce standards for the sizing of plasmids in experimental strains. These include the *S. typhimurium* strain X3306 (obtained from Roy Curtiss III) containing a 60 Mdal plasmid and *E. coli* strains C114 (obtained from Diane Taylor, University of Alberta), C153 (National Collection for Type Cultures #50005), C154 (National Collection for Type Cultures #50012), and C155 (National Collection for Type Cultures #50047) containing 86, 26, 72, and 46 Mdal plasmids, respectively.

Storage of Cultures

Stock cultures were stored at -20°C (primary stock) and -70°C (backup or long-term stock) in a solution of 1.0% peptone and 40% glycerol. All experimental cultures were subcultured from the -20°C stock to avoid any changes in the strain due to repeated subculturing. The -70°C stock culture was used to replace depleted -20°C stock cultures.

Preparation and Handling of Bacteria

Bacterial cultures were prepared by inoculating 4 ml of Difco Brain Heart Infusion broth (BHI) with a small amount of the -20°C stock culture. The broth was incubated (PSYCROTherm, New Brunswick Scientific) static overnight at 35°C and then subcultured to a growth medium. The growth conditions and medium used for subcultures are identified in experimental methods.

In most cases, bacteria were washed prior to use in experiments to remove the growth medium. Washing required pelleting the bacteria by centrifugation (Sorvall model RC-5B highspeed centrifuge, SS-34 rotor), (5000xg, 20 min, 4°C) and resuspending the pellet in either sterile saline (0.85% NaCl) or sterile glass distilled H₂O. The resuspended bacteria were then pelleted again by centrifugation and resuspended in the appropriate diluent. This procedure constituted one wash.

A non-selective plating medium, Trypticase Soy Agar with 0.6% Yeast Extract (TSY), was used for the enumeration of bacteria and the screening of cultures for contamination. Selective plating media (Hektoen and XLD agars, Difco) were used for the isolation of *S. typhimurium* from samples, such as feces and infected animal tissues, containing high numbers of background organisms. Plating of dilutions for counting was achieved by the spread plate method. All inoculated plates were incubated overnight at 35°C.

Development of Standard Curves
for Bacterial Strains

Standard curves of absorbance at 540 nm (A_{540}) vs concentration of bacteria (bacteria/ml) were developed for each of the bacterial strains (Appendix H). Bacteria from an 18 h BHI broth culture (10 ml) was washed 1x and diluted 1:10 in saline. This suspension was diluted further by a series of three serial dilutions (1:2), resulting in 1:10, 1:20, 1:40, 1:80 dilutions of the culture. The A_{540} of each dilution (4) was read (DMS 80 Spectrophotometer, Varian). The original 1:10 dilution was then diluted further in saline for enumeration by duplicate plating on TSY agar. The plate counts were then divided by their respective dilution factor in order to determine the concentration of bacteria in the original dilution. A curve plotting the A_{540} vs the concentration of bacteria for each of the four original dilutions (determined mathematically from the concentration of bacteria in the original 1:10 dilution) was constructed and its linear regression formula determined. The linear regression formula was used to determine the concentration of bacteria in washed cultures in order to adjust the concentration of bacteria to a desired value.

Tissue Culture Attachment
and Invasion Assay

An *in vitro* method for quantitative description of the interactions between epithelial cells and invasive

enteropathogenic bacteria has been previously described (60,62). A modification of this method was developed during this study.

Preparation and Maintenance of Epithelial Cell Monolayers

Henle 407 intestinal epithelial cells (ATCC CCL-6) were maintained in Eagle's basal medium (BME) with Hanks' balanced salts, 15 mM N-2-Hydroxyethyl-N-2-ethanesulfonic acid (HEPES), and 16 mM sodium bicarbonate (BME-1) containing 10% fetal bovine serum (FBS), penicillin (50 IU/ml) and streptomycin (50 ug/ml). The Henle cells were incubated (water-jacketed Incubator, Forma Scientific) at 37°C under 5% CO₂ in 75 cm² tissue culture flasks until they reached a confluent monolayer at which point they were used to make individual monolayers and/or passed to another tissue culture flask. Cells were never passed more than eight times to avoid the possibility of any change in cell characteristics.

Cell monolayers were prepared 48 h prior to use in an assay. A monolayer in a 75 cm² tissue culture flask was washed with 25 ml of Hanks' balanced salt solution without calcium or magnesium (HBSS-A) and treated with 5 ml of Sigma Cell Dissociation Solution (SCDS). The cells were incubated with SCDS for 30 sec and then 4.5 ml of the solution were removed from the flask. The remaining SCDS was allowed to stay on the cells for an additional 5 min to completely detach the cells from the plastic. Once free from the plastic, the

cells were suspended in 5 ml BME with 10% FBS and transferred to a 15 ml tissue culture tube. The cells were then gently pelleted by centrifugation (Sorvall model T6000B) (409xg, 5 min). The cell pellet was resuspended in 5 ml BME with 10% FBS. Trypan Blue exclusion was used to determine the number of viable cells by microscopically counting. The cell density was adjusted to 2.5×10^5 cells/ml by dilution in BME with 10% FBS. The adjusted cell suspension (0.5 ml) was added to the appropriate wells of a 24 well tissue culture plate and the plate was incubated for 48 h at 37°C under 5% CO₂. The cell density was approximately 5×10^5 after 48 h.

Preparation of Bacteria for Tissue Culture Assays

Bacteria for tissue culture assays were prepared by transferring 10 ul of an 18-h BHI broth culture into a 125 ml baffle flask containing 10 ml BHI and incubating the inoculated broth for 18 hr at 35 or 25°C under atmospheric conditions suitable to the assay being run. Anaerobic and aerobic conditions as well as temperature were investigated relative to their effect on the ability of the bacteria to adhere to and invade tissue culture cells in vitro. Anaerobic conditions were produced by placing an inoculated flask of BHI broth into an anaerobe jar (Oxoid) containing an activated gas generation envelope (BBL). The sealed jar was held static at 35°C. Anaerobic conditions were monitored by the presence of a methylene blue indicator strip within the jar. Aerobic

conditions were achieved by shaking an inoculated flask of BHI broth at 240 rpm. Incubation for 18 h produced a stationary phase culture which was pelleted by centrifugation and then washed 1x with saline. The washed bacteria were diluted 1:10 in saline and the absorbance of the suspension at 540 nm was determined spectrophotometrically. Using a standard curve of absorbance at 540 nm vs concentration of bacteria, the density of the bacteria in suspension was determined and adjusted to 1×10^7 bacteria/ml by dilution in BME with 20mM HEPES (BME-S). The concentration of bacteria was confirmed by duplicate plate counts.

Tissue Culture Attachment and Invasion Assay

A 24-well tissue culture plate organized into 4 rows of 3 wells containing monolayers ($\sim 5 \times 10^5$ cells/monolayer) and a row of 3 wells containing only BME-1 (control wells) was prepared 48 h prior to the start of each assay. The wells (monolayers and control wells) were washed 3x with 0.5 ml of Dulbecco's Phosphate Buffered Saline (DPBS) with 5% FBS. The wells in rows 1 and 2 were treated with 3% paraformaldehyde in DPBS, and the wells in rows 3, 4, and 5 were treated with DPBS-5% FBS for 5 min at 25°C. All wells were washed once with DPBS-5% FBS and treated with a blocking solution consisting of BME containing 20mM HEPES and 0.1% reagent grade gelatin (BME-G) for 1 h at 37°C under 5% CO₂. The blocking solution was removed and 0.5 ml of a prepared dilution (1×10^7

bacteria/ml in BME-S) added to each well, resulting in an estimated ratio of bacteria to cells of 10:1. The plate was centrifuged (500×g, 10 min) (Sorvall T6000B) to increase bacterial contact with the monolayers. The inoculated plate was incubated for 2 h at 37°C under 5% CO₂. Following this incubation the wells were washed 5x with DPBS-5% FBS (chilled to 4°C) with gentle rocking for 5 min at 4°C during each wash. The wells in rows 2, 4, and 5 were treated with 0.5 ml 0.5% N-lauroylsarcosine (sarcosine) in saline (warmed to 35°C) and the wells in rows 1 and 3 treated with 100 ug/ml gentamicin in DPBS-5% FBS (warmed to 35°C) for 10 min at 37°C under 5% CO₂. Sarcosine is a detergent which lyses the cells releasing any bacteria which are intracellular and strips attached bacteria from the surface of the wells. The sarcosine washes from the individual wells in each row were collected and combined. Two subsequent washes with sarcosine (without the 10 min incubation) followed for rows 2, 4, and 5. These washes were also collected and combined with the contents of the first sarcosine wash. Dilutions were prepared in saline and plated on TSY agar to enumerate bacteria. The remaining wells in rows 1 and 2 treated with gentamicin were incubated an additional 50 min at 37°C under 5% CO₂. Wells in rows 1 and 3 were washed 2x with DPBS-5% FBS (chilled to 4°C), each wash being rocked 5 min at 4°C, and then washed 3x with sarcosine in saline following the same procedure as above. These washes were also counted by plating on TSY agar.

Preparation of Infected Cells
for Electron Microscopy

A method for the preparation of cells infected with bacteria for electron microscopy was developed which combined protocols for the interaction of cells and bacteria in liquid a medium (61) with basic methods for the preparation of samples for electron microscopy (73). Bacteria for this protocol were prepared in a manner identical to that of the attachment and invasion assays. Cells in monolayers were detached from 75 cm² tissue culture flasks, resuspended in BME-10% FBS and diluted to a density of 1.11×10^6 cells/ml. The Henle 407 cells were infected by combining 0.2 ml of a prepared dilution of bacteria in BME-10% FBS (1×10^9 bacteria/ml) with 1.8 ml of a cell suspension also diluted in BME-10% FBS in a 15-ml tissue culture tube resulting in a bacteria to cell ratio of 100:1. The bacteria/cell suspension was then incubated for 3 hr at 35°C on a test tube roller. Karnofsky's fixative (2 ml) was added to the tube and held at 4°C for 1 h. Cells and bacteria were pelleted by centrifugation (Sorvall model T6000B) (100×g, 5 min) and washed 3x with 2 ml cacodylate buffer (0.1M NaCacodylate in PBS, pH 7.2) chilled to 4°C. The washed bacteria-cell pellet was then resuspended in 1 ml cacodylate buffer and warmed to 37° in a waterbath. Following the addition of 1 ml 4% agarose (SEAPREP ultra-low gelling temperature agarose) to the bacteria-cell suspension the mixture was transferred to BEEM

capsules (0.5 ml/capsule) and the bacteria\cells pelleted in the agarose by gentle centrifugation (Sorvall model RC-5B, HB-4 rotor) (100×g, 10 min). Gelling of the agarose was facilitated by chilling the BEEM capsules on ice for 10 min. The gelled agarose pellet was then removed from the BEEM capsule and the tip of this pellet containing the bacteria-cells removed with a razor blade. From this point the sample was processed following standard methods outlined in Appendix A.

Plasmid Preparation and Analysis

Plasmids were prepared from each of the experimental strains of *S. typhimurium*. The plasmid preparations were compared and analyzed using agarose gel electrophoresis and the results used to generate a comparative plasmid profile of each strain.

Preparation of Plasmids from Bacterial Strains

Most of the plasmid preparations were made from experimental and standard strains using CIRCLEPREP (BIO 101, Inc.), a rapid plasmid DNA purification kit. In several cases it was necessary, due to the lack of commercial reagents to use a method similar to that of CIRCLEPREP described by Marko et al. (51). The reagents for this method were produced in our lab and used following the CIRCLEPREP protocol as outlined in Appendix B.

Analysis of Plasmids Using Gel Electrophoresis

A 0.45% agarose gel (Sigma Type 5 Agarose in 1x Tris-Borate buffer) was poured on the gel platform of a submerged gel apparatus (Bio-Rad). The buffer tanks of the gel apparatus were filled with TBE buffer until the gel was submerged under approximately 2 mm of liquid. Ficoll loading buffer (0.25% Bromphenol Blue, 0.25% Xylene Cyanol, 15% Ficoll 400 in distilled H₂O, 6x) was diluted 1:6 with the plasmid preparations before loading. Samples were loaded (15 ul/well) onto the gel and run at 90 volts (LKB Broma 2197 power-supply) for 3 h. The buffer was circulated to avoid uneven heat distribution in the system. The gel was stained for 2 h in a solution of 1 ug/ml ethidium bromide in sterile distilled H₂O. The gel was then destained for 1.5 h in sterile distilled H₂O with changes of fresh H₂O at 15, 30, and 60 min. Photographs of the gel were taken using a UV light-table Polaroid C55 film and a Polaroid camera at F4.5 for 40 sec.

Sizing Plasmids

Plasmids were sized using a standard curve of the log of the migration distance for plasmids of known size vs the actual size of these plasmids. The curve was generated separately for each gel by including standard plasmid preparations. The size of the plasmid(s) in each experimental preparation was determined by measuring the distance migrated

on the gel and correlating this distance with its appropriate size relative to the standard curve prepared for the gel.

Animal Experimentation and Immunological Assays

Mouse models were used to demonstrate the effectiveness of *S. typhimurium* strains SL3235 and X4064 in eliciting secretory immunity against virulent strains of *S. typhimurium*. Serum and feces samples were collected from immunized mice and analyzed for isotype-specific antibodies against whole bacteria of the *S. typhimurium* strain SL3201 using an enzyme-linked immunosorbent assay (ELISA).

Immunization of Balb/cBy Mice

Balb/cBy mice were immunized using two different protocols. The first used an initial sub-cutaneous (sc) injection of live avirulent *S. typhimurium* followed later by an oral exposure to the same organism to boost the primary immune responses. The second protocol used an initial oral exposure to live avirulent *S. typhimurium* followed by two oral booster doses with the same organism.

Sub-cutaneous immunization. Bacteria from a 10-ml BHI broth culture grown overnight at 35°C on a shaker at 100 rpm were washed 2x with cold saline (4°C) and resuspended to its original volume in cold saline. The washed bacteria were diluted to 5×10^6 bacteria/ml in saline warmed to 35°C and 2 ml were transferred to a vial containing Ribi monophosphoryl

lipid A (MPL) + trehalose dimycolate (TDM) adjuvant (Ribi Adjuvant System, Ribi Immunochemicals) also warmed to 35°C. The vial was vortexed for 3 min to form an emulsion containing bacteria and adjuvant. The mice were immunized by sc injection of 0.1 ml of the emulsion into 2 sites located in the neck region. Each mouse received 0.2 ml of the emulsion which provided a dose of 1×10^6 bacteria.

Manual Oral Immunization. Bacteria from a 10-ml BHI broth culture grown overnight at 35°C on a shaker at 100 rpm were washed 2x with cold saline, recovered by centrifugation and resuspended in 10 ml cold saline. The resuspended bacteria were diluted to 5×10^8 /ml in 0.1% gelatin in saline. The mice were prepared for immunization by removing their drinking water 6 h prior to the inoculation. At the time of immunization each mouse received 30 ul of a 10% sodium bicarbonate solution to neutralize stomach acid and 20 ul of the diluted culture. The inoculation dose by this method was 1×10^7 bacteria/mouse.

Drinking-Water Immunization. Bacteria from a 10-ml BHI broth culture grown over-night at 35°C on a shaker at 100 rpm were pelleted by centrifugation (5000xg, 20 min). The pellet was resuspended in 10 ml of 0.1% peptone (Difco) and then diluted to 1×10^8 /ml in 0.1% peptone. Drinking water was removed from the mice for 6 h and then replaced with the diluted bacteria in 0.1% peptone. The bacterial suspension

was held for 24 h with the mice. This method did not allow determination of the dose.

Feces Collection

A method previously described for the preparation and storage of intestinal secretions for the analysis of antibody by Elson *et al.* (20) was used in this study. Fecal pellets were collected from the mice by placing them on a wire screen covering the bottom half of a Petri plate for 30 min. The fecal material was weighed and then suspended in 3 ml of 0.1 mg/ml trypsin inhibitor (Sigma, II-S) in 50 mM EDTA (pH 7.2). The pellets were broken up using a glass rod and vigorous vortexing in a 15 ml conical disposable centrifuge tube. Phosphate-buffered saline (PBS) was used to bring the volume up to 6 ml before the suspension was centrifuged (Sorvall model T6000B) (850xg, 10 min). Four ml of the supernatant was transferred to a 50 ml centrifuge tube and 100 μ l of a 100 mM solution of phenylmethylsulfonylfluoride (PMSF) in 95% ethanol was added to each tube. Centrifugation (22,530xg, 20 min) was used to further clear the supernatant of any suspended particles. For storage, 3 ml of the cleared supernatant was transferred to a vial with 30 μ l 100 mM PMSF, 30 μ l of a 1% solution of sodium azide, and 150 μ l of FBS to guard against the loss of antibody activity. Fecal preparations were stored frozen at -20°C . These preparations were analyzed for antibody activity using ELISAs. The concentration of the

feces in each sample was adjusted to 30 mg/ml and 100 ul applied to each test well which resulted in 3 mg of feces/well. The antibody activity was measured relative to positive and negative feces samples.

Serum collection

Serum was collected from the test mice by peri-orbital bleeding from the orbital venous sinus. Each mouse was anaesthetized using methoxyflurane (Metafane, Pittman-Moore) and its orbital venous sinus ruptured using a Pasteur pipet. Blood was drawn from the sinus into the Pasteur pipet and transferred to a microcentrifuge tube for storage. The collected blood was allowed to stand at 35°C for 1 h and then held at 4°C overnight. This treatment promoted clot formation and the separation of the serum. Centrifugation (Eppendorf microcentrifuge) for 10 min was used to pellet the red blood cells. The cleared serum was then transferred to a new microcentrifuge tube for storage at -20°C.

ELISA

An ELISA was used to analyze serum and feces samples for the presence of antibody specific for *S. typhimurium* strain SL3201. The method described below was developed in our lab using the guidance of an extensive publication on the subject (42).

Preparation of the Antigen. The antigen which served as the solid phase of this assay was comprised of whole viable

bacteria (*S. typhimurium* strain SL3201). To prepare the antigen, strain SL3201 was subcultured to 2 flasks each containing 25 ml of BHI broth and allowed to grow static overnight at 35°C. The cultures were combined, the bacteria washed 2x with cold (4°C) sterile distilled H₂O, and then resuspended in 5 ml cold sterile distilled H₂O. The dry weight of the bacteria/ml of suspension of bacteria was determined by drying 0.5 ml on each of three small aluminum planchets of known weight in a dessicator. The bacteria were dried to a point where their weight stabilized and this weight was recorded. The dry weight of the bacteria in each ml of the culture was then determined and the culture diluted to 20 ug of bacteria/ml in carbonate coating buffer (0.04 M Na₂CO₃, 0.06 M NaHCO₃, 0.02% NaN₃, in sterile distilled H₂O, pH 9.6) for application to 96 well Nunc-Immuno plates (Maxisorb, Nunc).

Preparation of ELISA Plates. Plates were prepared by adding 100 ul of prepared antigen to each of the wells of 96 well Nunc-Immuno plates excluding the 36 outside wells. The coated plates were then incubated overnight at 4°C to insure binding of the antigen to the polystyrene plate material. The plates were washed (each wash included 5 min of rocking) 3x with PBS using a manual ELISA washer (Corning model 26300) and treated with 200 ul/well of a blocking solution (2% chicken

egg albumin in PBS) for 4 h at 25°C. The blocking solution was removed and the plates sealed for storage at -20°C.

The ELISA Procedure. A coated and blocked plate was washed 3x with PBS. Samples (serum or feces) were diluted in sample buffer (0.1% bovine serum albumin (BSA) in PBS) and applied at a volume of 100 ul/well to the plate. The plate was incubated overnight at 4°C. Following 5 washes with PBST (PBS with 0.05% Tween 20), the plate was treated to a second blocking step with 200 ul/well of 1.0% BSA in PBS for 1 h at 25°C. The plate was washed 2x with PBST and treated with 100 ul/well of goat anti-mouse IgA, IgM, or IgG (Kirkegaard and Perry), depending on the antibody assay, for 2 h at room temperature. Working dilutions for ELISA were prepared with 0.1% BSA in PBST as follows: anti-mouse IgA, 1:4000, anti-mouse IgM, 1:2000, anti-mouse IgG, 1:2000. PBST was used to wash the plate 5 additional times before adding 100 ul/well of rabbit anti-goat IgG conjugated with alkaline phosphatase (Cappel) for 1.5 h at room temperature. The conjugate was diluted in 0.1% BSA-PBST to different concentrations depending upon the anti-mouse isotype; anti-mouse IgA, 1:6000, anti-mouse IgM, 1:4000, anti-mouse IgG, 1:4000. Following 5 washes with PBST, 200 ul of phosphatase substrate (Sigma 104 phosphatase substrate) diluted to a concentration of 1 mg/ml in diethanolamine buffer (50 mM MgCl₂, 9.7% diethanolamine in sterile distilled H₂O, pH 9.8) was dispensed in each reaction

well of the plate. The plate was covered with an adhesive cover (Corning) and incubated by floating in a 37°C circulating waterbath (Precision) for 2 h. The enzyme reaction was stopped by the addition of 100 ul of 3.0 M NaOH. The color produced by the phosphatase indicator system was analyzed by measuring the absorbance at 405 nm with an automated ELISA reader (Bio-Rad).

Foster Pup Studies

The presence of a protective secretory immune response in immunized Balb/cBy mice was investigated through the passive transfer of this immunity to unimmunized Balb/cBy foster pups. A method was developed which employed immunized lactating mothers as the source of the *S. typhimurium* specific antibody and unimmunized foster pups as the recipient of this immunity. Immunized female Balb/cBy mice were held with Balb/cBy males for 4 to 7 days after which time the males were removed. Any mouse showing signs of pregnancy was given an oral booster of the vaccine strain through its drinking water. The mother was left alone for 24 h following the birth of her pups at which time the natural pups were removed and replaced with 8 "foster" pups (pups born to an unimmunized mother) of approximately the same age. At this time the mothers and pups were moved to cages with wire bottoms to prevent continuous infection through coprophagy. Cotton bedding was used to prevent the pups from falling through the wire mesh. The

foster pups were then challenged orally with virulent *S. typhimurium* strain SL3201. A set of eight pups with an unimmunized mother were also challenged at this time to provide a control group. The challenge dose was prepared from a 10 ml BHI broth culture grown overnight at 35°C on a shaker at 100 rpm. The culture was washed 2x with cold saline (4°C), resuspended to its original volume in saline and diluted to 5×10^4 bacteria/ml with 0.1% gelatin in saline. Each pup was given 20 ul of the bacterial suspension orally using an Eppendorf pipettor and a small pipet tip. Challenge by this method resulted in a dose of 1×10^3 bacteria/pup. The pups in the test and control groups were then monitored for death over a 21 day period.

Feeding Studies for Measuring Passive Antibody Protection

Passive antibody protection provided by samples containing antibody specific for *S. typhimurium* strain SL3201 was evaluated by determining the implantation dose for strain SL3201 in mice. A test group of 17-day-old male and female Balb/cBy mice consisting of 4 sets of 5 mice were fed 3 doses of the sample at 24 h intervals. A dose consisted of 100 ul of the sample per mouse per feeding. A control group of 17-day-old male and female Balb/cBy mice also consisting of 4 sets of 5 mice were fed 3 doses of a negative sample which was either negative ascites or PBS depending on the test sample being evaluated, at 24 h intervals. A dose of the negative

sample also consisted of 100 ul per mouse per feeding. The mice were fed by gavage tube (intragastrically). The final feeding included the challenge bacteria. Graded doses of the challenge strain SL3201 were from a 10 ml BHI broth culture grown overnight (35°C, 100 rpm) by washing the bacteria 1x with cold saline and resuspending them in 10 ml of 0.1% gelatin in saline. The resuspended bacteria were diluted serially in the test sample (diluted 1:5 in 0.1% gelatin in saline) to provide 4 graded doses. A set of test mice and a set of control mice were challenged with 100 ul of each of the graded doses by intragastric feeding. The mice were held for 8 days and then killed by cervical dislocation. Rectal swabs (CalgiSwab) and spleens were taken from each of the mice. The rectal swabs were transferred to tubes containing 5 ml of tetrathionate broth (Difco) and the spleens placed in vials containing 4 ml BHI broth. The tubes were incubated at 35°C for 48 h. The selective and non-selective broths were streaked onto XLD agar, which was incubated for 24 h at 35°C. Growth of *S. typhimurium* strain SL3201 was confirmed by colony morphology and by serology using Difco poly A antiserum.

Abbreviations

Abbreviations used in this thesis are as follows; subcutaneous, sc; intraperitoneally, ip; peroral, po; megadalton, Mdal; kilobase, Kb; milliliter, ml; microliter,

ul; milligram, mg; microgram, ug; hour, h; second, sec; molar, M; millimolar, mM; brain-heart infusion, BHI; Trypticase Soy agar with 0.6% yeast extract, TSY; tris-borate-EDTA buffer, TBE; phosphate buffered saline, PBS; phosphate buffered saline with tween 20, PBST; Dulbecco's phosphate buffered saline, DPBS; Hanks' balanced salt solution, HBSS; fetal bovine serum, FBS; bovine serum albumin, BSA; chicken egg albumin, CEA; phenylmethylsulfonylfluoride, PMSF; N-2-hydroxyethyl-N-2-ethane sulfonic acid, HEPES; lipopolysaccharide, LPS; enzyme-linked immunosorbent assay, ELISA.

RESULTS

Plasmid Analysis

Plasmid preparations from each of the *S. typhimurium* strains used in this study were analyzed using agarose gel electrophoresis. The results are presented in Figures 1 and 2 and summarized in Table 1. Analysis of the plasmid profile for each strain demonstrated the presence of a plasmid of approximately 60 Mdal in size in *S. typhimurium* strains SL3201, SL3235, and SL1306 (Figure 2). Analysis of the migration distances of these plasmids using a standard curve generated on the same gel (Appendix E) confirmed their size at 60 Mdal (Figure 2). This plasmid was absent from the plasmid profiles of the plasmid-cured strain X3337 and the avirulent strain X4064 (Figure 1). A small plasmid of approximately 5 Mdal was present in strain SL3201 and strain SL3235 (Figure 2).

Table 1. Plasmids of the *S. typhimurium* strains used in this study. Small plasmid size is an approximation.

<u>Strain</u>	<u>Plasmids</u>	
	<u>Distance Migrated</u>	<u>Size (Mdal)</u>
SL3201	4.40 cm	60
	13.60 cm	5
SL3235	4.40 cm	60
	13.60 cm	5
SL1306	4.39 cm	60
X4064	-	-
X3337	-	-

